Investors

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high

cholesterol and diabetes, announces that it has entered into a development agreement with Centro Sperimentale Del Latte ("CSL") to synthesise and purify novel oligosaccharides (carbohydrates that consists of a small number of sugars) from microbial strains. CSL which is based in Italy, researches, develops, manufactures and distributes probiotics, starter cultures, moulds and yeasts for the pharmaceutical, nutraceutical, dairy, food and agricultural sectors all over the world.

The agreement provides OptiBiotix with development funding for the programme and extends the Company's OptiBiotic technology platform to a wider range of microbial species.

Stephen O'Hara, CEO of OptiBiotix, commented: "This development agreement reflects the progress we have made with our OptiBiotic technology platform. Increasing the number of microbial species is an exciting extension of our existing programme which broadens the range of product and partner opportunities. We are particularly pleased that CSL has recognised the opportunity presented by this work and has included its own strains in the development programme".

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

About CSL http://www.cslitalia.it

CSL, based in Italy, researches, develops, manufactures, and distributes probiotics, starter cultures, moulds and yeasts for the pharmaceutical, nutraceutical, dairy, food and agricultural sectors all over the world. CSL has two production plants in Italy, in the proximity of Milan: Zelo Buon Persico: a pharmaceutical production plant for the production of API and pharmaceutical bulk and Pasturago, for food, nutraceuticals and agriculture industries